

1 **Exploring the staining potential of GSK-3 inhibitors in bovine teeth:**
2 **a one-year laboratory investigation**

3 Jelena Karacic¹, Florin Eggmann¹, Roland Weiger¹, Lucia K. Zaugg²

4 **Accepted for publication August 7, 2023**

5 ¹Department of Periodontology, Endodontology, and Cariology, University Center for
6 Dental Medicine Basel UZB, University of Basel, Mattenstrasse 40, CH-4058 Basel,
7 Switzerland

8 ²Department of Reconstructive Dentistry, University Center for Dental Medicine Basel
9 UZB, University of Basel, Mattenstrasse 40, CH-4058 Basel, Switzerland

10

11

12 **Keywords**

13 Capping material, spectrophotometry, Tideglusib, tooth discoloration, vital pulp therapy

14

15 **Correspondence:**

16 Jelena Karacic

17 Klinik für Parodontologie, Endodontologie und Kariologie

18 Universitäres Zentrum für Zahnmedizin Basel UZB

19 Mattenstrasse 40

20 CH-4058 Basel

21 Tel. +41 61 267 26 82

22 E-Mail: jelena.karacic@unibas.ch

23

24

25 **Abstract**

26 GSK-3 inhibitors, such as Tideglusib (TG) and CHIR-99021 (CHIR), show promise in
27 stimulating reparative dentin formation. The aim of this study was to assess the
28 discoloration potential of TG and CHIR in an established *in vitro* model.

29 Enamel-dentin specimens made from bovine incisors were randomly allocated to five
30 groups (n=15 each): group bovine blood (BB), group dimethyl sulfoxide (DMSO), group
31 TG, group CHIR, and group mineral trioxide aggregate (MTA). Each specimen had a
32 central cavity in which the respective material was applied and sealed with resin-based
33 luting material. Color determination was conducted using a dental spectrophotometer
34 at t_0 (before filling), t_1 (immediately after filling), t_2 (after one week), t_3 (after one month),
35 t_4 (after three months), t_5 (after six months), and t_6 (after one year). Statistical analysis
36 involved descriptive statistics, Kruskal-Wallis tests, and analysis of variance ($\alpha=0.05$).
37 Group BB and group CHIR exhibited the most significant decrease in lightness (ΔL^*)
38 after one year ($\Delta L^* -4.7$ and $\Delta L^* -5.7$, respectively), whereas groups DMSO, TG, and
39 MTA showed minimal changes (DMSO ΔL^* : -0.3; TG ΔL^* : 1.4; MTA ΔL^* : -0.5). Group
40 BB and CHIR exhibited the highest ΔE values (6.4 ± 0.6 and 6.5 ± 0.8 , respectively).
41 Unlike CHIR, TG did not result in discoloration exceeding the threshold of visual
42 perception, defined by a ΔE value of 5.5, during the one-year observation period. This
43 laboratory study therefore suggests that TG could be utilized for indirect or direct pulp
44 capping without major discoloration concerns. However, additional research is
45 required to corroborate these findings.

46 **Introduction**

47 Dental injuries and deep carious lesions can lead to pulp exposure. When signs and
48 symptoms are absent, the primary objective of treating such lesions is to preserve the
49 vitality and health of the pulp tissue (RICUCCI ET AL. 2014; BJØRNDAL ET AL. 2019).
50 Various operative treatment approaches are available for maintaining pulp vitality,
51 including indirect and direct pulp capping, partial pulpotomy, and complete pulpotomy.
52 Preserving pulp vitality offers numerous benefits. The dentin-pulp complex can
53 continue fulfilling its developmental, defensive, and proprioceptive functions. In
54 addition, teeth with a vital pulp have a more favorable long-term prognosis regarding
55 tooth survival compared with those that have undergone root canal treatment (CAPLAN
56 ET AL. 2005; LEONG & YAP 2021).

57 The gold standard materials for indirect and direct pulp capping comprise calcium
58 hydroxide pastes and hydraulic silicate cements, including but not limited to mineral
59 trioxide aggregate (MTA), Biodentine, Endocem MTA, EndoSequence, and others
60 (DUNCAN ET AL. 2019; DAMMASCHKE ET AL. 2019; PARIROKH ET AL. 2018). Hydraulic
61 silicate cements exhibit high mechanical resistance and can set in both dry and moist
62 environments (CAMILLERI & PITT FORD 2006; PARIROKH & TORABINEJAD 2010;
63 TORABINEJAD & PARIROKH 2010; DAMMASCHKE ET AL. 2019). On the other hand, calcium
64 hydroxide pastes are less mechanically stable and susceptible to resorption and
65 porosities over time at the site of pulp capping (DAMMASCHKE ET AL. 2019). Both
66 hydraulic silicate cements and calcium hydroxide pastes release calcium hydroxide
67 ions during the setting process, which contribute to their high antibacterial properties
68 but may also cause local tissue damage owing to chemical irritation (SPÅNGBERG 1969;
69 MEADOW ET AL. 1984; BRISEÑO & WILLERSHAUSEN 1992).

70 It has been observed that localized cell death resulting from this mechanism leads to
71 the release of inflammatory mediators, which subsequently activate tissue

72 regeneration pathways and promote the formation of reparative dentin (BABB ET AL.
73 2017). This process involves the mobilization and proliferation of mesenchymal stem
74 cells from the pulp tissue, which can differentiate into new odontoblast-like cells and
75 initiate the secretion of reparative dentin (BABB ET AL. 2017).

76 Based on a molecular understanding of the cellular signaling pathways involved in
77 regenerative/reparative dentin formation, researchers have investigated
78 pharmacological treatments that directly activate these pathways using specific
79 molecules, inducing regulated reparative processes and promoting cellular
80 differentiation (NAKASHIMA & REDDI 2003; THESLEFF & TUMMERS 2008; GALLER ET AL.
81 2014). Collagen sponges loaded with these molecules have been utilized to administer
82 the treatment by placing them on the exposed pulp. Following application, controlled
83 degradation of these collagen sponges allows for their integration within the structure
84 of reparative dentin (NEVES ET AL. 2017; ZAUGG ET AL. 2020).

85 The novel treatment approach under investigation involves the use of glycogen
86 synthase kinase 3 (GSK-3) inhibitors as pharmacological agents. GSK-3, a protein
87 kinase, modulates the Wnt signaling cellular pathway (VISHWAKARMA ET AL. 2015).
88 Laboratory studies have demonstrated that GSK-3 inhibitors stimulate the proliferation
89 and viability of human dental pulp stem cells (HANNA ET AL. 2023; KORNSUTHISOPON ET
90 AL. 2023) and elicit the formation of reparative dentin in animal models following pulp
91 exposure (NEVES ET AL. 2017; ZAUGG ET AL. 2020). The Wnt signaling cellular pathway
92 assumes a crucial role in reparative dentin development in cases of pulp exposure.
93 Remarkably, the activity of the Wnt signaling pathway can also be activated in dentin
94 damage without pulp exposure, as observed in indirect pulp capping, resulting in the
95 formation of reactionary dentin and thickening of the dentin wall beneath the "near
96 exposure" (NEVES & SHARPE 2018). These findings suggest that novel medicaments

97 utilizing GSK-3 inhibitors hold promise for both direct and indirect pulp capping in the
98 future.

99 Tideglusib (TG), a non-competitive GSK-3 inhibitor, has been the subject of clinical
100 trials for Alzheimer therapy (ELDAR-FINKELMAN & MARTINEZ 2011; WANG ET AL. 2021).
101 Notably, no adverse reaction profile was described for TG (ELDAR-FINKELMAN &
102 MARTINEZ 2011). Another potent ATP-competitive GSK-3 inhibitor, CHIR-99021
103 (CHIR), an aminopyrimidine, has demonstrated its ability to activate the Wnt signaling
104 pathway, leading to enhanced self-renewal and pluripotency in mouse stem cells
105 (ELDAR-FINKELMAN & MARTINEZ 2011; WU ET AL. 2013). Both CHIR and TG have
106 exhibited promising outcomes in preclinical research regarding reparative dentin
107 formation, prompting considerations for their potential clinical application in dentistry
108 (NEVES ET AL. 2017; NEVES & SHARPE 2018; ZAUGG ET AL. 2020; ALAOHALI ET AL. 2022).
109 One drawback associated with early market-stage MTA products was their propensity
110 for significant tooth discoloration (NAIK & HEGDE 2005; LENHERR ET AL. 2012; KRSTL ET
111 AL. 2013; DETTWILER ET AL. 2016; ABUELNIEL ET AL. 2020). Recent investigations
112 attribute this discoloration to the presence of the radio-opaque marker bismuth oxide,
113 prompting the modification of formulations using alternative, non-discoloring radio-
114 opaque markers (KANG ET AL. 2015; KESKIN ET AL. 2015; XUEREB ET AL. 2016; MARCIANO
115 ET AL. 2019). These findings underscore the importance of laboratory research in
116 evaluating dental materials to identify potential adverse effects, including their
117 propensity for discoloration.

118 In recent years, there has been a surge in studies exploring the molecular mechanisms
119 and potential therapeutic applications of GSK-3 inhibitors. However, as of today, there
120 is a lack of published evidence regarding the discoloration potential of these inhibitors.
121 Thus, the objective of this study was to evaluate the discoloration potential of GSK-3
122 inhibitors in a well-established *in vitro* setup.

123 **Material and methods**

124 **Sample size calculation**

125 Based on data reported in a previous study, an a priori sample size calculation was
126 performed (LENHERR ET AL. 2012). A change of luminosity mean values (Lmean) of 92
127 to 90 with a standard deviation of 2.2 was assumed as the effect size between the
128 control group and the test groups. By setting the type I (two-sided) and type II error
129 rates at 5% and 20% respectively, establishing a significance level of 5%, and aiming
130 for a test power of 80%, a minimum of 10 samples per group was determined as
131 necessary. To ensure a prudent safety margin, accounting for the possibility of subtle
132 variations in discoloration outcomes, a total of 15 specimens per group were included.

133

134

135 **Specimen preparation**

136 A total of 75 specimens were produced using a methodology previously described in
137 detail by LENHERR ET AL. (2012). The source material consisted of bovine incisors
138 obtained from calves slaughtered in a commercial slaughterhouse and stored in tap
139 water at room temperature. The crown and root of each tooth were separated at the
140 cemento-enamel junction by using a diamond-coated cutting disk, which was
141 continuously cooled with water. From the middle third of each crown, rectangular
142 enamel-dentin slabs measuring 10 mm in length, 10 mm in width, and 3 mm in
143 thickness were excised. Subsequently, an oral surface cavity with dimensions of 2.5
144 mm in diameter and 2.0 mm in depth was created in each enamel-dentin slab using a
145 water-cooled cylindrical diamond bur. To ensure uniformity, the length, width, and
146 thickness dimensions of all specimens were verified using a digital caliper.

147

148 **Disinfection procedure**

149 The specimens were treated by immersing them in 1% sodium hypochlorite (NaOCl;
150 Toppharm Apotheke Hersberger, Basel, Switzerland) for a period of 30 minutes.
151 Subsequently, they were thoroughly rinsed with tap water, dried using compressed air,
152 and submerged in 20% ethylenediaminetetraacetic acid (EDTA, Toppharm Apotheke
153 Hersberger, Basel, Switzerland) for 2 minutes to eliminate the smear layer. After
154 rinsing with copious amounts of tap water and drying with air, the specimens were
155 immersed in 1% NaOCl for an additional 3 minutes. Finally, the specimens were
156 thoroughly washed with tap water and placed in 0.9% saline (Grosse Apotheke Dr. G.
157 Bichsel, Interlaken, Switzerland) for storage in an area with indirect sunlight.

158

159 **Experimental groups**

160 The specimens were randomly allocated to five groups using computer-generated
161 sequences created with free online software (www.randomizer.org). Each group
162 consisted of 15 specimens (Tab. I), and the same amount of liquid (1 μ L) and collagen
163 sponges (Kolspon; Eucare, Chennai, India) were used. The sponges were cut
164 according to the dimensions 2 mm x 2 mm x 2 mm and placed in the cylindrical cavity
165 prior to injecting the liquid. Group BB was designated as positive control group using
166 bovine blood (Bell Schweiz, Oensingen, Switzerland). In group DMSO, dimethyl
167 sulfoxide (DMSO, Sigma-Aldrich/ Merck, Darmstadt, Germany), a polar aprotic solvent
168 and organosulfur compound, was dispensed onto the sponge previously placed in the
169 cylindrical cavity of the specimens. In groups TG and CHIR, 50nM TG (Sigma-Aldrich/
170 Merck, Darmstadt, Germany) and 5 μ M CHIR (Sigma-Aldrich/ Merck, Darmstadt,
171 Germany), respectively, were dissolved in DMSO and subsequently administered into
172 each cavity. In group MTA, the non-discoloring formula of mineral trioxide aggregate
173 (MTA) powder and liquid (PD-MTA, Produits Dentaires SA, Vevey, Switzerland) were
174 thoroughly mixed at a ratio of 3:1 until a homogeneous mixture was achieved. The

175 resulting mixture had a creamy consistency and was promptly applied into the
176 cylindrical cavities without any sponge.

177 After the application of the material in each group, the cylindrical cavities were sealed
178 with self-adhesive resin-based luting material (RelyX Unicem2 Aplicap, 3M, St. Paul,
179 MN, USA). The luting material was light cured for 20 s at an irradiance of 907 mW/cm²
180 (SmartLite Focus, Dentsply Sirona, Charlotte, NC, USA). The tip of the curing light,
181 whose emission spectrum ranged from 420 nm to 540 nm, was positioned as close as
182 possible to the resin-based material without touching it during light curing. After light
183 curing, the specimens were placed in individual test tubes (Standard Micro Test Tube
184 3810, Eppendorf, Hamburg, Germany) containing 0.9% saline (Grosse Apotheke Dr.
185 G. Bichsel, Interlaken, Switzerland). The test tubes were then stored at room
186 temperature, ensuring they were kept away from direct sunlight.

187

188 **Spectrophotometric color determination**

189 Color determination was performed using a dental spectrophotometer (Vita
190 EasyShade Compact, Vita, Bad Säckingen, Germany) (LEHMANN ET AL. 2011). The
191 measurements were performed exclusively under the illumination provided by the
192 experimental setup's lamp (Lamp Trio 1 [max. 40W, 230V/50Hz] with a light-emitting
193 diode bulb [OSRAM, 40W, Classic B, 230V, E14, SES], both purchased from Migros,
194 Zurich, Switzerland) within a dark room. The spectrophotometric measurements were
195 taken at multiple time points, including baseline (t_0), immediately after filling (t_1), and
196 subsequently after one week (t_2), one month (t_3), three months (t_4), six months (t_5), and
197 one year (t_6). Before each group measurement, the spectrophotometer was calibrated
198 following the manufacturer's instructions. The color parameters recorded and
199 measured according to the Lab* color space were as follows: L^* (lightness), a^* (red-
200 green coordinates), and b^* (blue-yellow coordinates).

201

202 **Statistical analysis**

203 To describe the appearance of color, descriptive statistics were used for L^* , a^* , and
204 b^* values for each time interval and the color difference between baseline (t_0) and after
205 one year (t_6) was calculated using the following formula:

$$206 \Delta L^* = L^*_{t_6} - L^*_{t_0}$$

$$207 \Delta a^* = a^*_{t_6} - a^*_{t_0}$$

$$208 \Delta b^* = b^*_{t_6} - b^*_{t_0}$$

209 To assess the relative color change (ΔE) after one year, the following formula was
210 applied:

$$211 \Delta E^*_{ab} = ((\Delta L^*)^2 + (\Delta a^*)^2 + (\Delta b^*)^2)^{1/2}$$

212 The normality of the data was assessed using both the Kolmogorov-Smirnov and
213 Shapiro-Wilk tests. For between-group analysis, the Kruskal-Wallis test was employed.
214 Univariate and multivariate analysis of variance (ANOVA) were conducted for ΔE and
215 ΔL . Pairwise comparisons were performed using the Bonferroni and post-hoc Tukey
216 tests. The significance level was set at $\alpha = 0.05$. All analyses were carried out by an
217 unblinded investigator utilizing SPSS Statistics software (version 28, IBM, Armonk, NY,
218 USA).

219

220 **Results**

221 All values showed a normal distribution except TG at t_0 and t_6 for value a^* . The $L^*a^*b^*$
222 mean values at baseline (t_0) and after one year (t_6) and the differences over this period
223 ($\Delta L^*_{t_6-t_0}$, $\Delta a^*_{t_6-t_0}$, $\Delta b^*_{t_6-t_0}$) are reported in Tab. II. Group BB and CHIR presented the
224 most pronounced changes in lightness (ΔL^*) during the observation period with a
225 decrease of L^* after one year (BB $\Delta L^* -4.7 \pm 3.5$ CHIR $\Delta L^* -5.7 \pm 3.3$; Tab. II). A similar
226 range of L^* values with only slight changes after one year were found for group DMSO

227 with L^* -0.3 ± 1.7 , group TG with ΔL^* 1.4 ± 1.1 and group MTA with ΔL^* -0.5 ± 1.5 . A
228 decrease in L^* was observed in group DMSO and MTA, while L^* of group TG increased,
229 though not significantly. Group BB and CHIR showed significant changes in lightness
230 (ΔL^*) after one year of observation compared to the remaining groups DMSO, TG and
231 MTA ($p < 0.001$), while no significant difference was found between BB and CHIR.
232 The relative color changes (ΔE) after one year were reported highest for group BB and
233 CHIR with 6.4 ± 0.6 and 6.5 ± 0.8 , respectively. The remaining groups exhibited ΔE
234 values ≤ 4 (group DMSO: 2.7 ± 0.4), TG: 4.0 ± 0.2 and MTA: 2.8 ± 0.2 ; Tab. II). Significant
235 changes were recorded between group BB to group DMSO ($p < 0.001$), group TG
236 ($p < 0.01$) and group MTA ($p < 0.001$), but not to group CHIR ($p < 0.999$). Group CHIR
237 also showed significant differences compared with these three groups (DMSO
238 $p < 0.001$, TG $p < 0.005$, MTA $p < 0.001$).

239

240 **Discussion**

241 This study sought to explore the discoloration potential of two GSK-3 inhibitors,
242 specifically TG and CHIR. These GSK-3 inhibitors have garnered attention as potential
243 direct and indirect pulp capping materials for future use. Employing an established *in*
244 *vitro* setup, first described by LENHERR ET AL. (2012), our findings did not substantiate
245 the hypothesis that TG exhibited significant discoloration potential. However,
246 significant changes in lightness and color were observed in the case of CHIR.

247 The observed alterations in color for CHIR hold clinical significance, as previous
248 research has suggested that discolorations with a ΔE value exceeding 5.5 become
249 perceptible to the average patient and could be deemed unacceptable (DAY ET AL.
250 2011). Additionally, WESTLAND ET AL. (2017) investigated the threshold values at which
251 changes in color become noticeable to the average observer. Their study revealed that
252 a change of 1.1 ΔL^* , 3.2 Δa^* , and 1.5 Δb^* could be discerned. CHIR therefore, requires
253 additional assessment of its discoloration potential. Future research should focus on
254 comprehensively investigating the characteristics of CHIR products to ascertain their
255 suitability for clinical use in dentistry.

256 Compared with the findings of previous studies (LENHERR ET AL. 2012; DETTWILER ET
257 AL. 2016), our present investigation revealed a noticeably reduced discoloration effect
258 caused by bovine blood in the positive control group. This disparity can be attributed
259 to a subtle modification in our experimental approach. Specifically, like groups DMSO,
260 TG, and CHIR, the control group used only 1 μl of material, resulting in a minimal
261 amount of blood being employed. Additionally, our study did not include any groups
262 combining blood with drugs. These factors likely played a crucial role in the observed
263 decrease in discoloration intensity, highlighting the importance of both the quantity of
264 staining compounds and the interactions among different compounds in the process
265 of tooth discoloration. This finding underscores the significance of carefully considering

266 the dosage and combinations of substances to gain a comprehensive understanding
267 of discoloration mechanisms.

268 The $L^*a^*b^*$ color space is a three-dimensional color model that describes colors based
269 on three components: L^* represents lightness, a^* represents the red-green axis, and
270 b^* represents the yellow-blue axis. When assessing color changes in the bovine
271 specimens, the data of changes in $L^*a^*b^*$ values provided additional insight compared
272 with the use of ΔE , which represents the overall color difference between two samples.
273 While ΔE is a useful metric for comparing color changes, it does not provide detailed
274 information about the specific aspects of color alteration, such as lightness or hue
275 shifts. By analyzing the changes in $L^*a^*b^*$ values, specific aspects of color
276 transformation could be evaluated. It is noteworthy to observe that, despite the rigorous
277 process of sample randomization, the control group exhibited lower baseline L^* values
278 in comparison with the other groups. This disparity may introduce a subtle bias into the
279 results, warranting consideration in the interpretation of the findings.

280 A potential hindrance to the clinical utilization of GSK-3 inhibitors lies in the limited
281 availability of application forms. These inhibitors are solely accessible in a dissolved
282 state within DMSO, commonly combined with collagen sponges. In contrast, calcium
283 hydroxide exists in a paste form, enabling convenient application. However, ongoing
284 investigations are exploring alternative application forms for GSK-3 inhibitors, aiming
285 to enhance practicality and ease of use. For instance, recent studies conducted by
286 ALAOHALI ET AL. (2022) and ATILA ET AL. (2022) have evaluated the feasibility of
287 incorporating GSK-3 inhibitors into hydrogels. The utilization of hydrogels as a delivery
288 system for GSK-3 inhibitors offers notable advantages. Hydrogels can encapsulate
289 therapeutic agents, enabling controlled release and localized drug delivery.
290 Additionally, hydrogels can be tailored to exhibit desired physical properties, including
291 viscosity and gelation characteristics, allowing for precise application and retention at

292 the target site. Consequently, the utilization of hydrogels as an alternative application
293 form holds significant promise for facilitating the administration of GSK-3 inhibitors.

294 The findings of this laboratory study do not possess direct clinical relevance. Careful
295 consideration must be given to the inherent methodological limitations of this study.

296 First, the evaluation of possible discoloration resulting from the activation of the Wnt
297 pathway can only be effectively assessed in vital teeth. Therefore, it is crucial that
298 future studies investigating GSK-3 inhibitors in animal models monitor tooth color
299 changes over time and provide comprehensive data on discoloration or lack thereof.

300 Second, it should be noted that contact between GSK-3 inhibitors and saliva or dentinal
301 fluid could potentially lead to the formation of pigmented breakdown products, thus
302 increasing the likelihood of discoloration. In the present study, the materials were
303 applied under ideal laboratory conditions, without any fluid contamination.

304 Consequently, it remains unclear whether the application of GSK-3 inhibitors carries
305 inherent risks for tooth discoloration in clinical scenarios.

306 Third, the laboratory studies utilized bovine teeth specimens to assess the
307 discoloration potential of GSK-3 inhibitors. The utilization of bovine teeth, which exhibit
308 greater consistency in terms of shape and size compared to human teeth, served to
309 reduce variability across specimens. However, while the microstructure of bovine
310 dentin is similar to that of human dentin, notable differences exist in the shape and
311 diameter of dentinal tubules. Additional studies employing human teeth are therefore
312 necessary to enhance our understanding of the discoloration potential of GSK-3
313 inhibitors.

314 Owing to the absence of published studies investigating the discoloration potential of
315 GSK-3 inhibitors, direct comparisons with existing research cannot be drawn.

316 Nonetheless, this preliminary study offers valuable insights into the discoloration
317 potential of GSK-3 inhibitors. Considering the significance of dental esthetics in oral

318 health-related quality of life, it is important to take into account the discoloration
319 potential of direct and indirect capping materials alongside their therapeutic effects. To
320 comprehensively assess the true extent of the discoloration potential of TG, further *in*
321 *vitro* and *in vivo* studies are imperative.

322

323

324 **Conclusion**

325 Within the limitations of this laboratory study, the following conclusions were drawn:

- 326 • CHIR and TG, two GSK-3 inhibitors capable of promoting reparative dentin
327 formation, differ in their potential for inducing tooth discoloration *in vitro*.
- 328 • Whereas CHIR produced significant changes in lightness and color, the color
329 changes caused by TG remained below the threshold of visual perception.
- 330 • Additional research is necessary to advance our understanding of the
331 discoloration potential associated with GSK-3 inhibitors.

332

333 **Acknowledgments:**

334 The authors extend their gratitude to Bell AG in Oensingen, Switzerland, for providing
335 them the opportunity to extract bovine teeth. A special thanks goes to Dr. med. dent.
336 Christian Dettwiler, M. Sc., for his continuous instrumental-technical assistance.

337 **Zusammenfassung**

338 **Einleitung**

339 Massnahmen zur Vitalerhaltung bei der Behandlung von Zahnfrakturen und
340 fortgeschrittenen Kariesläsionen haben das Ziel, die Vitalität der Pulpa zu erhalten.
341 Gängige Methoden zur indirekten und direkten Pulpaüberkappung beinhalten die
342 Verwendung von Kalziumhydroxidpasten und hydraulischen Silikatzementen.
343 Entzündungsmediatoren fördern die reparative Bildung von Dentin durch die
344 Aktivierung von Geweberegenerationswegen. Inhibitoren der Glykogensynthase-
345 Kinase 3 (GSK-3), wie Tideglusib (TG) und CHIR-99021 (CHIR), haben sich als
346 vielversprechend erwiesen, um die Proliferation von Pulpastammzellen und die
347 Bildung von reparativem Dentin anzuregen. Obwohl das Verfärbungspotenzial
348 herkömmlicher Überkappungsmaterialien bekannt ist, gibt es derzeit nur begrenzte
349 wissenschaftliche Erkenntnisse über das Verfärbungspotenzial von GSK-3-Inhibitoren.
350 Daher hatte diese Studie zum Ziel, das Verfärbungspotenzial von GSK-3-Inhibitoren
351 zu bewerten.

352 **Material und Methoden**

353 In dieser Studie wurde ein etablierter *In-vitro*-Aufbau verwendet, um das
354 Verfärbungspotenzial von GSK-3-Inhibitoren zu untersuchen. Insgesamt wurden 75
355 Proben aus Rinderschneidezähnen präpariert, wobei rechteckige Schmelz-Dentin-
356 Proben mit standardisierten Kavitäten hergestellt wurden. Die Proben wurden einem
357 Desinfektionsverfahren mit Natriumhypochlorit und Ethylendiamintetraessigsäure
358 unterzogen. Anschliessend wurden sie zufällig fünf Versuchsgruppen zugewiesen:
359 Positivkontrolle (Rinderblut RB), Dimethylsulfoxid (DMSO), TG, CHIR und
360 Mineraltrioxidaggregat (MTA). Jede Gruppe bestand aus 15 Proben. Nach dem
361 Einbringen der jeweiligen Materialien in die Kavitäten und dem Verschluss der
362 Kavitäten mit Befestigungskomposit wurden die Proben in Reagenzgläsern mit

363 Kochsalzlösung bei Raumtemperatur gelagert. Die spektrophotometrische
364 Farbbestimmung wurde zu den Zeitpunkten t_0 (Vor Einlage), t_1 (unmittelbar nach
365 Einlage), t_2 (nach einer Woche), t_3 (nach einem Monat), t_4 (nach drei Monaten), t_5 (nach
366 sechs Monaten) und t_6 (nach einem Jahr) durchgeführt. Statistische Analysen,
367 einschließlich deskriptiver Statistik, Kruskal-Wallis-Test, ANOVA und paarweiser
368 Vergleiche, wurden durchgeführt, wobei das Signifikanzniveau bei $\alpha=0.05$ festgelegt
369 wurde.

370 **Resultate**

371 Die Ergebnisse der Studie zeigten signifikante Unterschiede in den
372 Farbveränderungen zwischen den Versuchsgruppen während des einjährigen
373 Beobachtungszeitraums. Die Gruppen RB und CHIR, die mit Rinderblut respektive mit
374 CHIR-99021 behandelt wurden, wiesen die deutlichste Abnahme der Helligkeit (L^*)
375 vom Ausgangswert (L_{t_0}) nach einem Jahr (L_{t_6}) auf, was auf eine erhebliche Verfärbung
376 hinweist (RB: $\Delta L^* -4,7$, CHIR: $\Delta L^* -5,7$). Die Gruppen DMSO, TG und MTA wiesen
377 minimale Veränderungen von L^* auf (ΔL^* innerhalb $\pm 1,5$), die jedoch statistisch nicht
378 signifikant waren. Die relativen Farbveränderungen (ΔE) nach einem Jahr waren bei
379 den Gruppen RB und CHIR am höchsten, mit signifikanten Unterschieden im Vergleich
380 zu den Gruppen DMSO, TG und MTA.

381 **Diskussion**

382 Die Ergebnisse zeigten, dass TG kein signifikantes Verfärbungspotenzial aufwies,
383 während CHIR signifikante Helligkeits- und Farbveränderungen verursachte. Diese
384 Farbveränderungen sind klinisch bedeutsam, da frühere Untersuchungen darauf
385 hindeuten, dass Farbveränderungen, die einen ΔE -Wert von 5,5 überschreiten, von
386 Patienten wahrgenommen werden. Die begrenzte Verfügbarkeit von GSK-3-
387 Inhibitoren in geeigneten Applikationsformen bleibt eine Herausforderung. Jüngste
388 Untersuchungen haben jedoch alternative Formen erforscht, wie z. B. die Einbindung

389 von GSK-3-Inhibitoren in Hydrogele, die Vorteile bei der kontrollierten
390 Wirkstofffreisetzung und zielgenauen Applikation bieten. Diese Studie hat
391 methodische Beschränkungen, daher ist es wichtig, weitere Untersuchungen an
392 vitalen Zähnen durchzuführen und potenzielle Verfärbungsrisiken durch den Kontakt
393 von GSK-3-Inhibitoren mit Speichel oder Dentinflüssigkeit zu bewerten. Trotz dieser
394 Einschränkungen liefert die Studie wertvolle Erkenntnisse zum Verfärbungspotenzial
395 von GSK-3-Inhibitoren. Erste Hinweise deuten darauf hin, dass TG möglicherweise
396 günstigere Eigenschaften in Bezug auf das Verfärbungspotenzial aufweist als CHIR.
397

398 **Résumé**

399 **Introduction**

400 Les mesures de préservation de la vitalité lors du traitement de fractures dentaires et
401 de lésions carieuses avancées ont pour objectif de préserver la vitalité de la pulpe. Les
402 méthodes courantes de coiffage pulpaire indirect et direct comprennent l'utilisation de
403 pâtes d'hydroxyde de calcium et de ciments silicatés hydrauliques. Les médiateurs de
404 l'inflammation favorisent la formation réparatrice de la dentine en activant les voies de
405 régénération tissulaire. Les inhibiteurs de la glycogène synthase kinase 3 (GSK-3),
406 tels que le tidéglusib (TG) et le CHIR-99021 (CHIR), se sont révélés prometteurs pour
407 stimuler la prolifération des cellules souches pulpaires et la formation de dentine
408 réparatrice. Bien que le potentiel de coloration des matériaux de coiffage traditionnels
409 soit connu, les connaissances scientifiques sur le potentiel de coloration des
410 inhibiteurs de GSK-3 sont actuellement limitées. C'est pourquoi cette étude avait pour
411 but d'évaluer le potentiel de coloration des inhibiteurs de GSK-3.

412 **Matériels et méthodes**

413 Dans cette étude, un dispositif *in vitro* bien établi a été utilisé pour évaluer le potentiel
414 de décoloration des inhibiteurs de GSK-3. Au total, 75 échantillons ont été préparés à

415 partir d'incisives bovines, en produisant des échantillons rectangulaires d'émail et de
416 dentine avec des cavités standardisées. Les échantillons ont été soumis à un
417 processus de désinfection avec de l'hypochlorite de sodium et de l'acide
418 éthylènediaminetétraacétique. Ils ont ensuite été répartis au hasard dans cinq groupes
419 expérimentaux : Contrôle positif (CP), diméthylsulfoxyde (DMSO), TG, CHIR et
420 agrégat de trioxyde minéral (MTA). Chaque groupe était composé de 15 échantillons.
421 Après l'introduction des matériaux respectifs dans les puits et la fermeture des puits
422 avec du composite de fixation, les échantillons ont été stockés dans des tubes à essai
423 contenant une solution saline à température ambiante. La détermination de la couleur
424 par spectrophotométrie a été effectuée à plusieurs moments sur une période d'un an.
425 Des analyses statistiques, y compris des statistiques descriptives, le test de Kruskal-
426 Wallis, l'ANOVA et des comparaisons par paires, ont été effectuées, le niveau de
427 signification étant fixé à $\alpha=0,05$.

428 **Résultats**

429 Les résultats de l'étude ont montré des différences significatives dans les
430 changements de couleur entre les groupes expérimentaux au cours de la période
431 d'observation d'un an. Le groupe CP, traité avec du sang bovin, et groupe CHIR, traité
432 par CHIR-99021, a présenté la diminution la plus significative de la luminosité (L^*) par
433 rapport à la valeur initiale (L_{t_0}) après un an (L_{t_6}), ce qui indique une décoloration
434 importante (CP : $\Delta L^* -4,7$. CHIR: $\Delta L^* -5,7$). Les groupes DMSO, TG et MTA ont
435 présenté des variations minimales de L^* (ΔL^* à l'intérieur de $\pm 1,5$), mais qui n'étaient pas
436 statistiquement significatives. Les changements de couleur relatifs (ΔE) au bout d'un
437 an étaient les plus élevés pour les groupes CP et CHIR, avec des différences
438 significatives par rapport aux groupes DMSO, TG et MTA.

439 **Discussion**

440 Les résultats ont montré que la TG ne présentait pas de potentiel de décoloration
441 significatif, tandis que la CHIR provoquait des changements significatifs de luminosité
442 et de couleur. Ces changements de couleur sont cliniquement significatifs, car des
443 études antérieures ont suggéré que les changements de couleur dépassant une valeur
444 ΔE de 5,5 sont perçus par les patients. La disponibilité limitée des inhibiteurs de GSK-
445 3 dans des formes d'application appropriées reste un défi. Cependant, des études
446 récentes ont exploré des formes alternatives, telles que l'incorporation d'inhibiteurs de
447 GSK-3 dans des hydrogels, qui présentent des avantages en termes de libération
448 contrôlée du principe actif et d'application ciblée. Cette étude présente des limites
449 méthodologiques, il est donc important de réaliser d'autres études sur des dents vitales
450 et d'évaluer les risques potentiels de décoloration liés au contact des inhibiteurs de
451 GSK-3 avec la salive ou le liquide dentinaire. Malgré ces limites, l'étude fournit des
452 informations précieuses sur le potentiel de coloration des inhibiteurs de GSK-3. Les
453 premières indications suggèrent que la TG pourrait présenter des propriétés plus
454 favorables que la CHIR en termes de potentiel de décoloration.

455

456 **References**

457

- 458 ABUELNIEL GM, DUGGAL MS, KABEL N: A comparison of mta and biodentine as
459 medicaments for pulpotomy in traumatized anterior immature permanent teeth:
460 A randomized clinical trial. Dent Traumatol 36:400-410 (2020)
- 461 ALAOHALI A, SALZLECHNER C, ZAUGG LK, SUZANO F, MARTINEZ A, GENTLEMAN E, SHARPE
462 PT: Gsk3 inhibitor-induced dentinogenesis using a hydrogel. J Dent Res
463 101:46-53 (2022)
- 464 ATILA D, CHEN CY, LIN CP, LEE YL, HASIRCI V, TEZCANER A, LIN FH: In vitro evaluation
465 of injectable tideglusib-loaded hyaluronic acid hydrogels incorporated with rg1-

466 loaded chitosan microspheres for vital pulp regeneration. *Carbohydr Polym*
467 278:118976 (2022)

468 BABB R, CHANDRASEKARAN D, CARVALHO MORENO NEVES V, SHARPE PT: Axin2-
469 expressing cells differentiate into reparative odontoblasts via autocrine wnt/ β -
470 catenin signaling in response to tooth damage. *Sci Rep* 7:3102 (2017)

471 BJØRNDAL L, SIMON S, TOMSON PL, DUNCAN HF: Management of deep caries and the
472 exposed pulp. *Int Endod J* 52:949-973 (2019)

473 BRISEÑO BM, WILLERSHAUSEN B: Root canal sealer cytotoxicity with human gingival
474 fibroblasts. Iii. Calcium hydroxide-based sealers. *J Endod* 18:110-113 (1992)

475 CAMILLERI J, PITT FORD TR: Mineral trioxide aggregate: A review of the constituents and
476 biological properties of the material. *Int Endod J* 39:747-754 (2006)

477 CAPLAN DJ, CAI J, YIN G, WHITE BA: Root canal filled versus non-root canal filled teeth:
478 A retrospective comparison of survival times. *J Public Health Dent* 65:90-96
479 (2005)

480 DAMMASCHKE T, GALLER K, KRASTL G: Aktuelle Empfehlungen zur Vitalerhaltung der
481 Pulpa. Wissenschaftliche Mitteilung der deutschen Gesellschaft für
482 Endodontologie und zahnärztliche Traumatologie. *Zahnärztl Mitt* 109:40-49
483 (2019)

484 DAY PF, DUGGAL MS, HIGH AS, ROBERTSON A, GREGG TA, ASHLEY PF, WELBURY RR,
485 COLE BO, WESTLAND S: Discoloration of teeth after avulsion and replantation:
486 Results from a multicenter randomized controlled trial. *J Endod* 37:1052-1057
487 (2011)

488 DEL SER T, STEINWACHS KC, GERTZ HJ, ANDRES MV, GOMEZ-CARRILLO B, MEDINA M,
489 VERICAT JA, REDONDO P, FLEET D, LEON T: Treatment of Alzheimer's disease
490 with the GSK-3 inhibitor tideglusib: A pilot study. *J Alzheimers Dis* 33:205-215
491 (2013)

492 DETTWILER CA, WALTER M, ZAUGG LK, LENHERR P, WEIGER R, KRASTL G: In vitro
493 assessment of the tooth staining potential of endodontic materials in a bovine
494 tooth model. *Dental Traumatol* 32:480-487 (2016)

495 DUNCAN HF, GALLER KM, TOMSON PL, SIMON S, EL-KARIM I, KUNDZINA R, KRASTL G,
496 DAMMASCHKE T, FRANSSON H, MARKVART M: European society of endodontology
497 position statement: Management of deep caries and the exposed pulp. *Int*
498 *Endod J* 52:923-934 (2019)

499 EGGMANN F, RIHS J, LENHERR P, WEIGER R, KRASTL G, ZAUGG LK: Spectrophotometric
500 insights: Calcium hydroxide influences tooth discolorations induced by short-
501 term application of antibiotic/corticosteroid pastes. *Clin Oral Investig* 25:1141-
502 1149 (2021)

503 ELДАР-FINKELMAN H, MARTINEZ A: Gsk-3 inhibitors: Preclinical and clinical focus on cns.
504 *Front Mol Neurosci* 4:32 (2011)

505 GALLER KM, EIDT A, SCHMALZ G: Cell-free approaches for dental pulp tissue
506 engineering. *J Endod* 40:41-45 (2014)

507 HANNA S, ALY R, ELDEEN GN, ADANERO VELASCO A, PÉREZ ALFAYATE R: Small molecule
508 gsk-3 inhibitors safely promote the proliferation and viability of human dental
509 pulp stem cells-in vitro. *Biomedicines* 11(2) (2023)

510 KANG SH, SHIN YS, LEE HS, KIM SO, SHIN Y, JUNG IY, SONG JS: Color changes of teeth
511 after treatment with various mineral trioxide aggregate-based materials: An ex
512 vivo study. *J Endod* 41:737-741 (2015)

513 KESKIN C, DEMIRYUREK EO, OZYUREK T: Color stabilities of calcium silicate-based
514 materials in contact with different irrigation solutions. *J Endod* 41:409-411
515 (2015)

516 KORNSUTHISOPON C, TOMPKINS KA, OSATHANON T: Tideglusib enhances odontogenic
517 differentiation in human dental pulp stem cells in vitro. *Int Endod J* 56:369-384
518 (2023)

519 KRASTL G, ALLGAYER N, LENHERR P, FILIPPI A, TANEJA P, WEIGER R: Tooth discoloration
520 induced by endodontic materials: A literature review. *Dent Traumatol* 29:2-7
521 (2013)

522 LEHMANN KM, DEVIGUS A, IGIEL C, WENTASCHEK S, AZAR MS, SCHELLER H: Repeatability
523 of color-measuring devices. *Eur J Esthet Dent* 6:428-435 (2011)

524 LENHERR P, ALLGAYER N, WEIGER R, FILIPPI A, ATTIN T, KRASTL G: Tooth discoloration
525 induced by endodontic materials: A laboratory study. *Int Endod J* 45:942-949
526 (2012)

527 LEONG DJX, YAP AU: Vital pulp therapy in carious pulp-exposed permanent teeth: An
528 umbrella review. *Clin Oral Investig* 25:6743-6756 (2021)

529 MARCIANO MA, CAMILLERI J, LUCATELI RL, COSTA RM, MATSUMOTO MA, DUARTE MAH:
530 Physical, chemical, and biological properties of white mta with additions of
531 alf(3). *Clin Oral Investig* 23:33-41 (2019)

532 MEADOW D, LINDNER G, NEEDLEMAN H: Oral trauma in children. *Pediatr Dent* 6:248-251
533 (1984)

534 NAIK S, HEGDE AH: Mineral trioxide aggregate as a pulpotomy agent in primary molars:
535 An in vivo study. *J Indian Soc Pedod Prev Dent* 23:13-16 (2005)

536 NAKASHIMA M, REDDI AH: The application of bone morphogenetic proteins to dental
537 tissue engineering. *Nat Biotechnol* 21:1025-1032 (2003)

538 NEVES VC, BABB R, CHANDRASEKARAN D, SHARPE PT: Promotion of natural tooth repair
539 by small molecule gsk3 antagonists. *Sci Rep* 7:39654 (2017)

540 NEVES VCM, SHARPE PT: Regulation of reactionary dentine formation. *J Dent Res*
541 97:416-422 (2018)

542 PARIROKH M, TORABINEJAD M: Mineral trioxide aggregate: A comprehensive literature
543 review—part i: Chemical, physical, and antibacterial properties. *J Endod* 36:16-
544 27 (2010)

545 PARIROKH M, TORABINEJAD M, DUMMER PMH: Mineral trioxide aggregate and other
546 bioactive endodontic cements: an updated overview - part I: vital pulp therapy.
547 *Int Endod J* 51:177-205 (2018)

548 RICUCCI D, LOGHIN S, SIQUEIRA JF, JR: Correlation between clinical and histologic pulp
549 diagnoses. *J Endod* 40:1932-1939 (2014)

550 SPÅNGBERG L: Biological effects of root canal filling materials. 7. Reaction of bony
551 tissue to implanted root canal filling material in guineapigs. *Odontol Tidskr*
552 77:133-159 (1969)

553 THESLEFF I, TUMMERS M: Tooth organogenesis and regeneration. *Stembook*,
554 Cambridge (2008)

555 TORABINEJAD M, PARIROKH M: Mineral trioxide aggregate: A comprehensive literature
556 review—part ii: Leakage and biocompatibility investigations. *J Endod* 36:190-
557 202 (2010)

558 VISHWAKARMA A, SHARPE P, SHI S, RAMALINGAM M: Stem cell biology and tissue
559 engineering in dental sciences. Elsevier, Waltham (2015)

560 WANG L, BHARTI, KUMAR R, PAVLOV PF, WINBLAD B: Small molecule therapeutics for
561 tauopathy in alzheimer's disease: Walking on the path of most resistance. *Eur*
562 *J Med Chem* 209:112915 (2021)

563 WESTLAND S, LUO W, LI Y, PAN Q, JOINER A: Investigation of the perceptual thresholds
564 of tooth whiteness. *J Dent* 67:11-14 (2017)

565 WU Y, AI Z, YAO K, CAO L, DU J, SHI X, GUO Z, ZHANG Y: Chir99021 promotes self-
566 renewal of mouse embryonic stem cells by modulation of protein-encoding gene

567 and long intergenic non-coding RNA expression. *Exp Cell Res* 319:2684-2699
568 (2013)

569 XUEREB M, SORRENTINO F, DAMIDOT D, CAMILLERI J: Development of novel tricalcium
570 silicate-based endodontic cements with sintered radiopacifier phase. *Clin Oral*
571 *Investig* 20:967-982 (2016)

572 ZAUGG LK, BANU A, WALTHER AR, CHANDRASEKARAN D, BABB RC, SALZLECHNER C,
573 HEDEGAARD MAB, GENTLEMAN E, SHARPE PT: Translation approach for dentine
574 regeneration using GSK-3 antagonists. *J Dent Res* 99:544-551 (2020)

575

576

578
579
580

Tables

Tab. I Composition of the materials used in the different experimental groups.

Group	Material	Composition/Details	Mixing information	Manufacturer
BB	Bovine blood	Positive control group	N/A	Bell Schweiz, Oensingen, Switzerland
DMSO	DMSO	Dimethyl sulfoxide	N/A	Sigma-Aldrich/Merck, Darmstadt, Germany
TG	Tideglusib	Concentration: 50nM	Tideglusib dissolved in DMSO/PBS*	Sigma-Aldrich/Merck, Darmstadt, Germany
CHIR	CHIR99021	Concentration: 5µM	CHIR 99021 dissolved in DMSO/PBS*	Sigma-Aldrich/Merck, Darmstadt, Germany
MTA	PD-MTA	Tricalcium silicate, Dicalcium silicate, Tricalcium aluminate, Calcium oxide, Calcium tungstate.	Full content of one sachet mixed with distilled water for 30 s to a creamy consistency	Produits Dentaires SA, Vevey, Switzerland

581 *PBS*: phosphate buffered saline (DMSO/PBS ratio = 0.2%v/v)

582 *PD-MTA*: Produits Dentaires Mineraltrioxidaggregat

583

Tab. II Mean values \pm standard deviation (SD) and 95% confidence intervals (CI) of L^* , a^* and b^* values of the materials at baseline (t_0) and after one year (t_6) and the difference over this period ($\Delta L^*t_6-t_0$; $\Delta a^*t_6-t_0$; $\Delta b^*t_6-t_0$; $\Delta E_{t_6-t_0}$)

Group	L^*					a^*					b^*					ΔE	
	t_0		t_6		t_6-t_0	t_0		t_6		t_6-t_0	t_0		t_6		t_6-t_0	t_6-t_0	
	Mean \pm SD	95% CI	Mean \pm SD	95% CI	ΔL^*	Mean \pm SD	95% CI	Mean \pm SD	95% CI	Δa^*	Mean \pm SD	95% CI	Mean \pm SD	95% CI	Δb^*	$\Delta E \pm$ SD	95% CI
BB	86.1 \pm 0.8	84.4-87.8	81.4 \pm 0.7	80.0-82.8	-4.7	0.5 \pm 0.2	0.2-0.9	-0.3 \pm 0.2	0.8-0.2	-0.8	20.7 \pm 0.4	19.8-21.5	20.1 \pm 0.6	18.7-21.4	-0.6	6.4 \pm 0.6	5.1-7.0
DMS	90.0 \pm 0.7	88.6-91.5	89.7 \pm 0.5	88.6-90.8	0.3**	-0.3 \pm 0.1	-0.7-(-0.02)	-0.5 \pm 0.1	0.7-(-0.3)	-0.2*	19.9 \pm 0.5	18.8-20.9	17.8 \pm 0.6	16.6-19.1	-2.0	2.7** \pm 0.4	1.7-3.0
TG	90.7 \pm 0.4	89.9-91.5	92.1 \pm 0.4	91.2-92.9	1.4**	-0.3 \pm 0.2	-0.6-0.03	-1.0 \pm 0.1	1.1-(-0.8)	-0.7	20.5 \pm 0.5	19.5-21.5	17.1 \pm 0.5	16.0-18.2	-3.5**	4.0* \pm 0.2	3.7-4.5
CHIR	91.5 \pm 0.5	90.3-92.6	85.8 \pm 0.6	84.5-87.0	-5.7	-0.7 \pm 0.1	-1.0-(-0.5)	-1.0 \pm 0.1	1.2-(-0.8)	-0.3	20.1 \pm 0.4	19.2-21.0	17.5 \pm 0.5	16.5-18.5	-2.6*	6.5 \pm 0.8	4.8-8.0
MTA	91.5 \pm 0.4	90.7-92.4	91.0 \pm 0.4	90.1-92.0	0.5**	-0.6 \pm 0.1	-0.8-(-0.5)	-1.0 \pm 0.1	1.2-(-0.9)	-0.4	19.8 \pm 0.4	19.0-20.7	17.6 \pm 0.3	16.9-18.4	-2.2	2.8** \pm 0.2	2.4-3.0

BB: control group blood, DMSO: group DMSO, TG: group Tideglusib, CHIR: group CHIR99021, MTA: PD-MTA, L^* : lightness, a^* : red-green coordinates, b^* : blue-yellow coordinates, ΔE : relative color change. $*p < 0.05$ denotes a significant difference when compared with control group BB. $**p < 0.001$ indicates a highly significant difference when compared with control group BB.

